It's not that the mode of action would change Pete. The risk if the when the human liver and its unique enzyme systems conjugate this drug, it's proposed activity could be altered. It might not work at all. It might not be able to be raised to levels where this genetic activity occurs. The anticipated doses might be found to be totally off base - as they were calculated on animals with different liver enzyme systems. The preclinical work gives a good outline to follow - but surprises happen all the time in a phI trial. This is novel agent with novel mechanism of action - they don't have a blueprint to follow for a similar that has been tested on humans. Both positive or negative surprises could be in store. Obviously - we're here because we're confident that this careful team will deliver us positive results.